Our publications
EPI-PHARE disseminates its results to French Health Authorities, in the form of public reports, and publishes them in international peer-reviewed scientific journals.
Search by
Type of study
- Benefits and risks of health products
- Impact measurment studies
- Methods and tools
- Response to alerts or crisis
- Use of health products in real life
Keyword
- Aids
- Alert or crisis situation
- AMR
- Androcur
- Anti-infective
- Anti-TNF
- Anti-VEGF
- Antibiotics
- Antiepileptic drugs
- Antihypertensive drugs
- Aspirin
- Beyfortus
- Biologics
- Biosimilar
- Breast cancer
- Cancer
- Chemotherapy
- Children
- Chlormadinone acetate
- Codeine
- Colonoscopy
- Confinement
- Contraception
- Covid-19
- Cyproterone acetate
- Desogestrel
- Elderly people
- Epidemic
- Finasteride
- Hydroxychloroquine
- Immunosuppressive drugs
- Inflammatory bowel disease
- Levonorgestrel
- Levothyrox
- Macrolides
- Massive exposure
- Medical devices
- Medroxyprogesterone
- Meningioma
- Multiple sclerosis
- Mycophenolate
- Nirsevimab
- Nomegestrol acetate
- Ophthalmology
- Oral anticoagulants
- PPI
- Pregnancy
- PrEP
- Progestogens
- Prophylaxis
- Proton pump inhibitors
- Psoriasis
- Rheumatoid arthritis
- Rituximab
- Semaglutide
- Specific population
- Statins
- Statistics
- Suicide
- Thiopurines
- Transplant
- Trastuzumab
- Truvada
- Vaccines
- Valproate
- Valsartan
- Vasectomie
- VIH
- Wegovy
- Women of childbearing age
Period
Going further